Framingham, MA, United States of America

Abraham Scaria

USPTO Granted Patents = 28 (Patent Applications = 14)

EPO Patents = 13 (Patent Applications = 12)

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 152(Granted Patents)

Location History:

Bridgewater, NJ (US) (2017 - 2021)
Cambridge, MA (US) (2014 - 2022)
Framingham, MA (US) (2000 - 2024)

Company Filing History:

Crispr Therapeutics Ag

The United States of America As Represented by the

patent

5. 1 out of 2,925

University of Florida Research Foundation, Incorporated

patents

6. 1 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12344842 - Compositions and methods for treating and preventing macular degeneration (2025-07-01),

2. 12247201 - Materials and methods for treatment of autosomal dominant retinitis pigmentosa (2025-03-11),

3. 12241078 - AAV vectors for retinal and CNS gene therapy (2025-03-04),

4. 12215316 - Materials and methods for treatment of usher syndrome type 2A (2025-02-04),

5. 12173290 - Materials and methods for controlling gene editing (2024-12-24),

6. 12122998 - Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP) (2024-10-22),

7. 11896651 - Gene editing of deep intronic mutations (2024-02-13),

8. 11299715 - Use of iNOS inhibitors to increase viral yield in culture (2022-04-12),

9. 11118177 - Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP) (2021-09-14),

10. 11084864 - Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof (2021-08-10),

11. 11072792 - Materials and methods for treatment of usher syndrome type 2A (2021-07-27),

12. 10995328 - Materials and methods for treatment of autosomal dominant cone-rod dystrophy (2021-05-04),

13. 10982228 - AAV vectors for retinal and CNS gene therapy (2021-04-20),

14. 10822391 - Fusion proteins and methods for inhibiting IL-17 pathways (2020-11-03),

15. 10821193 - Adeno-associated viral vectors for treating myocilin (MYOC) glaucoma (2020-11-03),

Title: The Innovative Contributions of Abraham Scaria in Gene Therapy

Introduction: Abraham Scaria, based in Framingham, MA, has made significant contributions to the field of gene therapy, holding an impressive portfolio of 26 patents. His innovative work primarily focuses on advancing treatments for ocular and central nervous system (CNS) disorders.

Latest Patents: Among his latest patents, Scaria has developed improved recombinant adeno-associated virus (rAAV) vectors designed for enhanced gene therapy. His innovations include methods for treating ocular diseases and CNS disorders through advanced compositions of rAAV particles. One notable patent addresses the treatment of Usher Syndrome Type 2A, providing essential materials, methods, and kits for editing the USH2A gene in human cells. These inventions are pivotal for enhancing therapeutic options for patients suffering from these genetic conditions.

Career Highlights: Scaria's professional journey includes valuable experiences at prominent companies such as Genzyme Corporation and Crispr Therapeutics. His work in these organizations has contributed to groundbreaking advancements in genetic research and treatment methodologies.

Collaborations: Throughout his career, Scaria has collaborated with notable coworkers, including Samuel C. Wadsworth and Peter Pechan. These partnerships have fostered an environment of innovation and have played a crucial role in the development of his patents.

Conclusion: Abraham Scaria's contributions to gene therapy have significantly impacted the landscape of medical treatment for ocular and CNS disorders. With a robust portfolio of patents and a commitment to innovation, Scaria continues to be a key figure in advancing the potential of gene therapy solutions.

This text is generated by artificial intelligence and may not be accurate.